Show simple item record

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.

dc.contributor.authorFolprecht, G
dc.contributor.authorPericay, C
dc.contributor.authorSaunders, Mark P
dc.contributor.authorThomas, A
dc.contributor.authorLopez, R
dc.contributor.authorRoh, J
dc.contributor.authorChistyakov, V
dc.contributor.authorHöhler, T
dc.contributor.authorKim, J
dc.contributor.authorHofheinz, R
dc.contributor.authorAckland, S
dc.contributor.authorSwinson, D
dc.contributor.authorKopp, M
dc.contributor.authorUdovitsa, D
dc.contributor.authorHall, M
dc.contributor.authorIveson, T
dc.contributor.authorVogel, A
dc.contributor.authorZalcberg, J
dc.date.accessioned2016-05-25T15:29:38Zen
dc.date.available2016-05-25T15:29:38Zen
dc.date.issued2016-04-18en
dc.identifier.citationOxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study. 2016: Ann Oncolen
dc.identifier.issn1569-8041en
dc.identifier.pmid27091810en
dc.identifier.doi10.1093/annonc/mdw176en
dc.identifier.urihttp://hdl.handle.net/10541/610749en
dc.description.abstractThe combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleOxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.en
dc.typeArticleen
dc.contributor.departmentUniversity Cancer Center / Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germanyen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractThe combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.


This item appears in the following Collection(s)

Show simple item record